SB203580 increases G-CSF production via a stem-loop destabilizing element in the 3’ untranslated region in macrophages independently of its effect on p38 MAPK activity by unknown
RESEARCH Open Access
SB203580 increases G-CSF production via a
stem-loop destabilizing element in the
3’ untranslated region in macrophages
independently of its effect on p38
MAPK activity
Shwu-Fen Chang1, Huai-Ci Li2, Yu-Pei Huang2, Wen-Ju Tasi2, Yuan-Yi Chou2 and Shao-Chun Lu2*
Abstract
Background: Granulocyte-colony stimulating factor (G-CSF) is a major regulator of the production and survival of
neutrophils. Regulation of G-CSF expression is complex and occurs at both transcription and post-transcription
levels. Two distinct types of cis-acting elements in the 3’ untranslated region (3’UTR) of G-CSF mRNA have been
identified as destabilizing elements; these consist of adenylate uridylate-rich elements (AUREs) and a stem–loop
destabilizing element (SLDE). Regulation of the stability of mRNA by p38 mitogen-activated protein kinase (MAPK)
has been indicated to be linked to AUREs in the 3’UTR. However, whether p38 MAPK is involved in the regulation
of the stability of G-CSF mRNA has not been elucidated. This study investigated the effect of SB203580, an inhibitor
of p38 MAPK, on the lipopolysaccharide-induced G-CSF expression in macrophages at the post-transcription level.
Results: Our study showed surprising results that SB203580 augmented the lipopolysaccharide-induced increase in
the G-CSF mRNA levels in RAW264.7 mouse macrophages, mouse bone marrow-derived macrophages and in THP-1
human macrophages. This effect was also seen in p38α MAPK knockdown RAW264.7 cells, showing that it was not
due to inhibition of p38 MAPK activity. In the presence of actinomycin D, the decay of G-CSF mRNA was slower in
SB203580-treated cells than in control cells, showing that SB203580 increased the stability of G-CSF mRNA. Reporter
genes containing luciferase with or without the 3’UTR of G-CSF were constructed and transfected into RAW264.7
cells and the results showed that the presence of the 3’UTR reduced the luciferase mRNA levels and luciferase
activity. Furthermore, SB203580 increased the luciferase mRNA levels and activity in RAW264.7 cells transfected with
the luciferase reporter containing the 3’UTR, but not in cells transfected with the luciferase reporter without the
3’UTR. Mutations of the highly conserved SLDE in the 3’UTR abolished these effects, showing that the SLDE was
essential for the SB203580-induced increase in the stability of mRNA.
Conclusions: SB203580 increases G-CSF expression in macrophages by increasing the stability of G-CSF mRNA via
its 3’UTR, and the effect was not due to its inhibition of p38 MAPK activity. The results of this study also highlight a
potential target for boosting endogenous production of G-CSF during neutropenia.
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Background
Granulocyte colony-stimulating factor (G-CSF), a glyco-
protein, stimulates the proliferation of neutropenic
progenitor cells and their differentiation to granulocytes
and also activates mature neutrophils [1]. Production of
neutrophils is critical for innate host defense against
microbial pathogens and is tightly controlled. G-CSF is
primarily secreted by monocytes and macrophages, but is
also produced by endothelial cells, fibroblasts, and bone
marrow stromal cells [2]. Transcriptional control of
G-CSF expression has been intensively studied. Binding
elements for nuclear factor- kappaB (NF-κB), nuclear
factor for IL-6 (NF-IL6), and octamer transcription factors
in the G-CSF promoter are highly conserved and are
required for endotoxin-mediated induction of G-CSF tran-
scription in macrophages [3]. However, post-transcriptional
regulation of the stability of G-CSF mRNA has been less
well studied. Two distinct types of cis-acting elements in
the 3’ untranslated region (3’UTR) of G-CSF mRNA have
been identified as destabilizing elements; these consist of
adenylate uridylate-rich elements (AUREs), with the core
sequence AUUUA, and a stem–loop destabilizing element
(SLDE) [4]. AUREs are the best characterized mRNA desta-
bilizing elements, and have been identified in the 3’UTR of
many transiently expressed cytokine mRNAs, including
those for tumor necrosis factor-alpha (TNF-α), interleukin-
1 beta (IL-1β), cyclooxygenase-2 (COX-2), and interferon-γ;
however, they are also known to increase the stability of
mRNA in macrophages treated with lipopolysaccharide
(LPS) [5]. In NIH 3 T3 cells, the SLDE in the 3’UTR of G-
CSF mRNA operates by a mechanism different from that
used by AUREs, as mRNA degradation directed by AUREs
is inhibited by calcium flux generated by a calcium iono-
phore, whereas that directed by SLDE is not [4, 6].
SB203580 is originally identified as an inflammatory
cytokine synthesis inhibitor and subsequently found to be
a selective inhibitor of p38α and p38β mitogen-activated
protein kinases (MAPKs) [7]. SB203580 inhibits the cata-
lytic activity of p38 MAPK by competitively binding to the
ATP pocket and is widely used to elucidate the roles of
p38 MAPK in a wide range of biological systems. Genetic
deletion of one form, p38β MAPK, in mice does not affect
LPS-induced production of cytokine [8], suggesting that
p38βMAPK is not involved in the immune and inflamma-
tory response, while the other form, p38α MAPK, is
known to regulate synthesis of cytokines by increasing
mRNA half-life [7]. Inhibition of p38 MAPK activity by
SB203580 in LPS-treated THP-1 macrophages leads to
rapid degradation of several AURE containing mRNAs
such as COX-2, IL-1β, IL-6, and MAP2K6 [9]. However,
in contrast to this decrease in these mRNA levels in
response to SB203580 treatment, in the present study, we
observed that SB203580 increased G-CSF mRNA and
protein levels in LPS-treated RAW264.7 and THP-1
macrophages. Since AUREs increase the stability of
COX-2, IL-1β, IL-6, and MAP2K6 mRNAs through a
p38 MAPK-dependent pathway [9], it is possible that
the SB203580-induced increase in the G-CSF mRNA
levels is mediated by AUREs and might be mediated
by the other destabilizing element, SLDE. Here, we
show that the SB203580-induced increase in the G-
CSF mRNA levels does not involve p38α MAPK and
that the SLDE in the 3’UTR is essential for
SB203580-induced G-CSF mRNA stabilization.
Methods
Materials
Dulbecco’s modified Eagle’s medium (DMEM), RPMI
1640 medium, and fetal bovine serum (FBS) were
obtained from Hyclone Laboratories (Logan, UT, USA).
TRIzol reagent and penicillin/streptomycin were obtained
from GibcoBrl/LifeTechnologies (Rockville, MD, USA).
LPS from Escherichia coli (serotype 0111:B4) and actino-
mycin D, a transcription inhibitor, were purchased from
Sigma-Aldrich (St. Louis, MO, USA). Mouse macrophage
colony-stimulating factor (M-CSF) was obtained from
PeproTech (Rocky Hill, NJ, USA.). Mouse monoclonal
anti-β-actin antibody was purchased from Chemicon
(Temecula, CA, USA), p38α MAPK mouse mAb and
rabbit polyclonal anti-mouse phospho-p38 antibodies
were from Cell Signaling Technology (Danvers, MA,
USA), and peroxidase-conjugated anti-rabbit or anti-
mouse IgG antibodies were from Amersham-Pharmacia
Biotech (Piscataway, NJ, USA). The pGL3-Basic and
phRLTK reporter plasmids, Dual-Luciferase® Reporter
Assay System, and MMLV reverse transcriptase were from
Promega (Madison, WI, USA). The SuperFect Transfec-
tion reagent was purchased from Qiagen (Hilden,
Germany). The mouse G-CSF Quantikine ELISA kit was
from R&D Systems (Minneapolis, MN, USA). The
pharmacological p38 MAPK inhibitors SB203580,
SB202190, SB239063, PD169316, and SKF86002 and the
inactive SB203580 analog SB202474 were purchased from
Calbiochem (San Diego, CA, USA) and dissolved in
dimethyl sulfoxide (DMSO).
Cell culture
RAW264.7, a murine macrophage cell line was cultured
in DMEM supplemented with 10 % FBS, 4 mM
glutamine, 100 U/ml of penicillin, and 100 μg/ml of
streptomycin at 37 °C in 5 % CO2 as described previously
[10]. THP-1, a human acute monocytic leukemia cell line
was cultured in RPMI 1640 medium containing 10 % FBS,
100 U/ml of penicillin, and 100 μg/ml of streptomycin
and induced to differentiate to macrophages using 160
nM phorbol 12-myristate-13-acetate as described previ-
ously [10]. Mouse bone marrow-derived macrophages
(BMDMs) were differentiated from bone marrow cells as
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described previously [11]. The procedures for the use of
mouse bone marrow cells were reviewed and approved by
the National Taiwan University Institutional Animal Care
and Use Committee. Briefly, mouse bone marrow cells
were aspirated from the tibias and femurs of 16- to
20 week-old C57BL/6 J mice and cultured in a humidified
incubator in an atmosphere of 5 % CO2 at 37 °C in
complete culture medium containing 25 % L-929 cell
conditioned medium on bacteriologic Petri dishes for
7 days. After trypsinization, the cells were counted and
seeded at 1×106 cells/ml in complete culture medium
containing 10 ng/ml of M-CSF overnight before further
experiments. L-929 cells conditioned medium was
prepared by incubating 5×105 L-929 cells in a T-150 flask
(Corning, NY, USA) for 1 week in complete culture
medium (DMEM supplemented with 10 % FBS,
2 mM L-glutamine, 1 mM sodium pyruvate, 100 U/ml of
penicillin, and 100 μg/ml of streptomycin).
Effect of p38 MAPK inhibitors on G-CSF mRNA and
protein levels
G-CSF mRNA and protein levels were compared in cells
treated with 0.1 % DMSO (vehicle) and cells treated with
p38 MAPK inhibitors (10 μM unless otherwise specified)
for the indicated time or in cells pretreated for 30 min
with DMSO or p38 MAPK inhibitor, followed by
addition of 100 ng/ml of LPS and further incubation for
the indicated time.
Quantification of G-CSF protein in culture medium
The concentration of G-CSF in the culture medium
from RAW264.7 cells was measured using a mouse G-
CSF Quantikine ELISA kit (R & D Systems, Minneapolis,
MN, USA) according to the manufacturer’s instructions.
RNA isolation and mRNA analyses
Total cellular RNA was isolated from cells using TRIzol®
reagent (Invitrogen, Carlsbad, CA, USA), and RNA con-
centrations determined from the absorbance at 260 nm.
First-strand cDNA was synthesized from total RNA
using MMLV reverse transcriptase (RT) with oligo-dT as
primer. Levels of G-CSF and GAPDH mRNA were
determined either by semi-quantitative PCR (RT-PCR)
or by real-time quantitative PCR (RT-qPCR) on an
iCycler instrument (BioRad, Hercules, CA, USA) as
indicated. The specific primer sets were designed using
Beacon designer 5.0 (Premier Biosoft International, Palo
Alto, CA, USA) and are listed in Table 1. The amplified
DNA fragments were confirmed by sequencing. The fold
induction of mRNA expression was quantified by densi-
tometry (RT-PCR) or by the ΔΔCt-method (RT-qPCR)
as described previously [12].
Plasmid construction
A 107 bp (-81 to +26) fragment of the GAPDH
promoter was PCR-amplified from mouse genomic
DNA using the primers listed in Table 1 and cloned
into the MluI/BglII sites at the 5’ end of the lucifer-
ase gene in the pGL3-basic reporter plasmid to gener-
ate the plasmid Gp-LUC. The mouse G-CSF mRNA
3’UTR fragment from nucleotide 691 to 1363 was
PCR-amplified from cDNA generated from RAW264.7
cell total RNA using the primers listed in Table 1 and
was cloned into XbaI site of the Gp-LUC reporter
plasmid to obtain the Gp-LUC-3’UTR reporter
plasmid. Site-directed mutagenesis to generate three
Gp-LUC-3’UTR SLDE mutants, SLDE M1, M2, and
M3, was performed by PCR using mutant oligonucle-
otides. All constructs were verified by sequencing.
Table 1 Equences of the primers used in this study
Primers for RT-PCR
Primers Sequence
mouse G-CSF Forward 5’-CTCAACTTTCTGCCCAGAGG-3’
Reverse 5’-CTGGAAGGCAGAAGTGAAGG-3’
human G-CSF Forward 5’-CACTCTGGACAGTGCAGGAAG-3’
Reverse 5’-CGACACCTCCAGGAAGCTCTG-3’








mouse G-CSF Forward 5’-TTGGCAACATCCAGCTGAAG-3’
Reverse 5’-GCAGGCTCTATCGGGTATTTCC-3’






Photinus luciferase Forward 5’-GCCTGAAGTCTCTGATTAAGT-3’
Reverse 5’-ACACCTGCGTCGAAGA-3’
Renilla luciferase Forward 5’-GCAAGGGTTGGTCGTGAGG-3’
Reverse 5’-TCATCCGTTTCCGTTCTG-3’











The underlined sequences are restriction enzyme sites created to facilitate cloning
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Reporter gene activity assay
To evaluate the effects of the G-CSF 3’UTR on luciferase
activity, 0.75 μg of Gp-LUC, Gp-LUC-3’UTR, or an
SLDE mutant reporter plasmid was mixed with 0.75 μg
of phRLTK plasmid, then the mixture was transiently
transfected into RAW264.7 cells. Briefly, RAW264.7 cells
were plated in 24-well plates and cultured overnight
before transfection with Superfect reagent as described
previously [10]. Four hours after transfection, in most
cases, the cells were either left untreated or were
pretreated with DMSO or SB03580 for 30 min before and
during incubation with 100 ng/ml of LPS for 20 h, while,
in some cases, the transfected cells were incubated with
DMSO or SB03580 for 20 h without subsequent addition
of LPS. At 24 h after transfection, Photinus and Renilla
luciferase activities in the cell lysates were assayed using
the Dual-Luciferase Reporter Assay System (Promega,
Madison, WI, USA), and the light intensity produced
by Photinus luciferase (test plasmid) was normalized
to that produced by Renilla luciferase (control
plasmid). In some experiments, Photinus luciferase and
Renilla luciferase mRNA levels were determined by RT-
qPCR using the specific primers listed in Table 1.
Knockdown of p38 by RNA interference
The pLKO.1-short hairpin RNA (shRNA) plasmids
encoding an shRNA targeting firefly luciferase (5’–CA
AATCACAGAATCGTCGTAT–3’) or one targeting
mouse p38α (5’–CCTCTTGTTGAAAGATTCCTT–3’)
were obtained from the National RNAi Core Facility at
the Academia Sinica, Taiwan, and were transfected,
together with pMD.G and pCMV delta8.91, into a
HEK293T packaging cell line (National RNAi Core Facility,
Taiwan) using the calcium phosphate method, and culture
supernatants containing lentivirus were collected from
the medium 60 h later. For knockdown experiments,
RAW264.7 cells were transduced for 24 h with the
collected virus supernatants in the presence of
polybrene (8 μg/ml), then infected cells were selected
with puromycin (10 μg/ml) for 10 days.
Western blot analysis
Cells were washed with ice-cold phosphate-buffered
saline and lysed with RIPA buffer (20 mM Tris-HCl,
pH 7.5, 150 mM NaCl, 5 mM EDTA, 0.5 % NP-40,
0.5 % Triton X-100, 0.1 % SDS, 1 mM NaF, 1 mM
PMSF, 1 mM Na3VO4, and 1 μg/ml of leupeptin),
then the lysates were centrifuged at 500 × g for
10 min at 4 °C and samples of the supernatants
(20 μg of protein/lane) were separated by SDS-PAGE
on a 10 % gel and transferred to a PVDF membrane,
which was then blocked overnight at 4 °C with block-
ing buffer (10 mM Tris-HCl, pH 8.0, 0.15 M NaCl,
0.1 % Tween 20, and 5 % fat-free milk). The blots
were then incubated for 1 h at room temperature
with 0.5 μg/ml of mouse monoclonal anti-p38α anti-
body, rabbit polyclonal anti-phospho-p38 antibodies,
or mouse monoclonal anti-β-actin antibody and for
40 min at room temperature with peroxidase-
conjugated anti-rabbit or anti-mouse IgG antibodies,
then bound antibody was detected using an improved
chemiluminescence detection system (NEN, Boston,
MA, USA). Protein concentrations were determined
by the Bradford method (DC Protein Assay, Bio-Rad,
Hercules, CA, USA).
Statistical analysis
Results are shown as the mean ± SD. Differences
between means were evaluated using Student’s t test and
were considered significant at p <0.05.
Results
SB203580 increases G-CSF protein and mRNA levels in
LPS-stimulated RAW264.7 cells, BMDMs and THP-1 cells
The effect of SB203580, a p38 MAPK inhibitor, on G-
CSF protein and mRNA levels in LPS-stimulated
macrophages was examined by incubating RAW264.7
cells with SB203580 or DMSO for 30 min before and
during treatment with LPS for various times, then G-
CSF protein and mRNA levels were measured by
ELISA or RT-PCR, respectively. The results showed
that the G-CSF protein levels in the medium (Fig. 1a)
and the G-CSF mRNA levels (Fig. 1b) were low in
untreated RAW264.7 cells, but increased considerably
after, respectively, 6 h or 4 h of LPS treatment and
that SB203580 pretreatment resulted in a further
significant increase in both G-CSF protein and mRNA
levels. Whereas IL-1β mRNA levels were increased
after 2 h and reached its peak at 4 h of LPS treat-
ment and that SB203580 pretreatment resulted in a
significant decrease in IL-1β mRNA levels (Fig. 1b).
The effect of SB203580 on LPS-induced G-CSF
expression was also evaluated in mouse BMDMs. As
in RAW264.7 cells, G-CSF protein (Fig. 1c) and
mRNA (Fig. 1d) were undetectable in untreated
BMDMs, but levels of both were increased after,
respectively, 8–16 h or 4–8 h of LPS treatment, and
SB203580 pretreatment resulted in a further signifi-
cant increase in the presence of LPS that lasted for at
least 16 h. Whereas IL-1β mRNA were upregulatd by
LPS and reached its peak at 8 h of LPS treatment
and that SB203580 pretreatment resulted in a signifi-
cant decrease in IL-1β mRNA levels (Fig. 1d). These
results were unexpected. To confirm the effect of
SB203580 on the G-CSF mRNA levels, RAW264.7
cells were incubated with 0, 1, 5, or 10 μM SB203580 for
30 min before and during treatment with 100 ng/ml of
LPS for 6 h, then the G-CSF mRNA levels were measured
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by RT-PCR and RT-qPCR and the results showed that the
G-CSF mRNA levels increased in a dose-dependent
manner in response to SB203580 treatment (Fig. 1e). In
contrast, IL-1β mRNA levels decreased in a dose-
dependent manner in response to SB203580 treatment
(Fig. 1e, upper panel).
Fig. 1 SB203580 enhances G-CSF expression in LPS-treated macrophages. RAW264.7 cells (a and b) and BMDMs (c and d) were incubated with
DMSO (vehicle) or 10 μM SB203580 for 30 min, then 100 ng/ml of LPS was added and incubation continued for 0 to 16 h, then G-CSF protein
levels in the medium were measured by ELISA (a and c) and G-CSF and IL-1β mRNA levels were determined by RT-PCR and analyzed by gel
electrophoresis (b and d). (e) RAW264.7 cells were incubated with DMSO or 1, 5, or 10 μM SB203580 for 30 min, then LPS (100 ng/ml) was added
and incubation continued for 6 h, then G-CSF and IL-1β mRNA levels were determined by RT-PCR (upper panel). Levels of G-CSF mRNA were
determined by RT-qPCR (lower panel), normalized to GAPDH mRNA levels, and expressed relative to the value in the cells treated only with LPS,
set as 1. (f) THP-1 macrophages were pretreated with DMSO or 10 μM SB203580 for 30 min, then LPS or PBS was added and incubation continued for 0
to 6 h. Total RNA was then isolated and levels of G-CSF and GAPDH (internal control) mRNA determined by RT-PCR and analyzed by gel electrophoresis.
The results in (a) and (e) are the mean ± SD for three independent experiments. *p < 0.05, compared to the group treated only with LPS. (d) The data
shown in (b) and (f) are typical of the results obtained in three independent experiments. The data shown in (c) and (d) are typical of the results obtained
in two independent experiments
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The effects of SB203580 and LPS on the G-CSF
mRNA levels were also evaluated in THP-1 human mac-
rophages, and as with mouse macrophages, SB203580
enhanced the LPS-induced increase in the G-CSF
mRNA levels, the effect being maximal after 4 h of LPS
treatment (Fig. 1f ). Taken together, Fig. 1 shows that
SB203580 enhances the LPS-induced increase in G-CSF
protein and/or mRNA levels in both mouse and human
macrophages.
SB203580 enhancement of the LPS-induced increase in
the G-CSF mRNA levels is not due to p38 MAPK inhibition
To test whether other p38 MAPK inhibitors also en-
hanced the LPS-induced increase in the G-CSF mRNA
levels, RAW264.7 and THP-1 macrophages were pre-
treated with DMSO or SB203580, SB202190, PD169316,
SB239063, or SKF86002 for 30 min, then LPS was added
for 6 h and the G-CSF mRNA levels were measured by
RT-qPCR. As shown in Fig. 2a, pretreatment with
SB203580, SB202190, or PD169316 resulted in 3.6- to
4.7-fold increase, and SKF86002 pretreatment resulted
in a 1.8-fold increase, in the G-CSF mRNA levels
compared to LPS-treated cells; however, SB239063
pretreatment had no effect. Similar results were also ob-
tained using human THP-1 cells (Fig. 2b). The inhibitory
effect of these inhibitors and the lack of effect of the
inactive SB203580 analogue SB202474 on LPS-induced
p38 MAPK activation in THP-1 cells was confirmed by
Western blot analysis of phosphorylation of HSP-27, a
downstream effector of p38 MAPK (Fig. 2c). Thus, these
results show that not all p38 MAPK inhibitors increase
LPS-induced the G-CSF mRNA levels, suggesting that
the SB203580-induced enhancement of the LPS-induced
increase in the G-CSF mRNA levels might be unrelated
to its effect of inhibiting p38 MAPK activity. We there-
fore examined whether SB203580 induced an increase in
Fig. 2 Effects of various p38 MAPK inhibitors on LPS-induced G-CSF mRNA in RAW264.7 and THP-1 macrophages. RAW264.7 cells (a) and THP-1
(b) were pretreated for 30 min with DMSO or 10 μM SB203580, SB202190, PD169316, SB239063, or SKF86002, then 100 ng/ml of LPS was added
and incubation continued for 6 h, then the G-CSF mRNA levels were determined by RT-qPCR, normalized to GAPDH mRNA levels, and expressed
relative to the value in the DMSO control, set as 1. The values are the mean ± SD for three separate experiments. *p < 0.05, compared to the DMSO-
treated cells. (c) THP-1 macrophages were left untreated (left lane) or were pretreated for 30 min with DMSO or 10 μM SB203580, SB202190, PD169316,
SB239063, or SKF86002, then 100 ng/ml of LPS was added and incubation continued for 30 min, then levels of phosphorylated HSP27, phosphorylated
p38 MAPK, and total p38 MAPK were determined by Western blotting
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the G-CSF mRNA levels in cells p38 MAPK was not
activated, i.e. in cells in which not treated with LPS. As
shown in Fig. 3a, no p38 MAPK phosphorylation was
detected in untreated RAW264.7 cells, but was detected
after 15 min of LPS treatment and reached a maximum
at 30 min. Although the G-CSF mRNA levels were low
in untreated RAW264.7 cells, it could be detected after
35 cycles of RT-PCR and, as shown in Fig. 3b, SB203580
treatment for various times in the absence of LPS re-
sulted in a 3-fold increase in the G-CSF mRNA levels
starting after 4 h of treatment and lasting at least till 8 h.
Since p38α MAPK is the major isoform, we then investi-
gated whether it was involved in the SB203580-induced
enhancement of the LPS-induced increase in the G-CSF
mRNA levels using p38α MAPK knockdown in
RAW264.7 cells by infection with a lentivirus carrying a
specific shRNA targeting p38α MAPK or a lentivirus
carrying luciferase shRNA as a negative control.
Figure 4a shows that shRNA-mediated p38α MAPK
knockdown resulted in an 80 % decrease in levels of
p38α MAPK protein. The p38α MAPK and control
knockdown cells were then pretreated with SB203580
for 30 min and treated with LPS for 6 h, then the G-CSF
mRNA levels were measured by RT-qPCR. As shown in
Fig. 4b, SB203580 induced a significant approximately 4-
fold increase in the G-CSF mRNA levels in both LPS-
treated p38α MAPK knockdown cells and control
knockdown cells (Luc). The results support the above
findings that the SB203580-induced enhancement of the
LPS-induced increase in the G-CSF mRNA levels is
independent of p38α MAPK.
The SLDE in the 3’UTR is essential for SB203580-induced
enhancement of the LPS-induced increase in the G-CSF
mRNA levels
Since the 3’UTR of G-CSF mRNA contains several AUREs
and an SLDE, both of which are mRNA stabilizing/desta-
bilizing elements, it was possible that the SB203580-
induced enhancement of the LPS-induced increase in the
G-CSF mRNA levels was due to an increase in the stability
of mRNA. To examine the effect of SB203580 on the sta-
bility of G-CSF mRNA, the G-CSF mRNA levels were de-
termined by RT-qPCR in cells pretreated with DMSO or
SB203580 for 30 min and subsequent LPS treatment for
5 h, followed by treatment with 4 μg/ml of actinomycin D
for 0–3 h. As shown in Fig. 5a, in DMSO/LPS-treated
cells, actinomycin D treatment resulted in a decrease in
the G-CSF mRNA levels with a half-life of 2.7 h, while, in
SB203580/LPS-treated cells, the half-life of G-CSF mRNA
was approximately 3.7 h. In the absence of LPS, degrad-
ation of G-CSF mRNA was markedly slower in cells
treated for 30 min with SB203580 than in those treated
with DMSO when subsequently treated with actinomycin
D (Fig. 5b). Together, these results show that SB203580
increases the stability of G-CSF mRNA. To determine
whether the G-CSF 3’UTR was involved in SB203580-
mediated mRNA stabilization, we first constructed a
control reporter plasmid, Gp-LUC, which containing the
luciferase gene driven by the GAPDH promoter, then
cloned the 3’UTR from mouse G-CSF 3’ to the luciferase
Fig. 3 SB203580 induces G-CSF expression in RAW264.7 cells in the
absence of LPS stimulation. a RAW264.7 cells were left untreated
(lane 1) or were incubated with LPS for 15 to 60 min (lanes 2–4),
then phosphorylated p38, total p38, and β-actin levels were analyzed
by Western blotting. b RAW264.7 cells were incubated with DMSO
or 10 μM SB203580 for 0 to 8 h, then levels of G-CSF and GAPDH
(internal control) mRNA were determined by RT-PCR and analyzed
by gel electrophoresis (upper panels). The G-CSF mRNA levels were
normalized to those for GAPDH mRNA and expressed relative to the
value in the DMSO-treated cells at 0 h (relative value = 1) (lower panels).
The results are the mean ± SD for three independent experiments.
*p < 0.05, compared to the DMSO-treated cells
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gene in the Gp-LUC plasmid to create a chimeric Gp-
LUC-3’UTR reporter that could transcribe the luciferase
mRNA containing the G-CSF 3’UTR. RAW264.7 cells
were transfected with Gp-LUC or Gp-LUC-3’UTR, then,
at 4 h after transfection, were incubated with DMSO or
SB203580 for 20 h. In the absence of SB203580, the
luciferase mRNA levels were significantly lower in cells
transfected with Gp-LUC-3’UTR than in those transfected
with Gp-LUC, and SB203580 treatment had no effect on
the luciferase mRNA levels (Fig. 6a) or luciferase activity
Fig. 4 SB203580 enhances the LPS-induced increase in G-CSF expression in p38α MAPK knockdown RAW264.7 macrophages. a RAW264.7 cells were
infected with either lentivirus carrying specific shRNA for p38α MAPK or lentivirus carrying luciferase shRNA (Luc) and selected with puromycin (5 μg/ml)
for 3 days, then p38α MAPK and β-actin protein levels in the cells were determined by Western blotting (upper panel), and mRNA levels were deter-
mined by RT-qPCR (lower panel). b Control knockdown (Luc) and p38α MAPK knockdown cells were pretreated for 30 min with DMSO or 10 μM
SB203580, then 100 ng/ml of LPS was added and incubation continued for 6 h, then the G-CSF mRNA levels were determined by RT-qPCR, normalized
to GAPDH mRNA levels, and expressed relative to the value for the appropriate DMSO control, set as 1. The results are the mean ± SD for three independ-
ent experiments. *p< 0.05, compared to the corresponding cells not treated with SB203580
Fig. 5 SB203580 slows G-CSF mRNA degradation in RAW264.7 macrophages. a RAW264.7 cells were pretreated for 30 min with DMSO or 10 μM
SB203580, then 100 ng/ml of LPS was added and incubation continued for 5 h, then the cells were treated with actinomycin D (4 μg/ml) for 0, 1,
2, or 3 h. The G-CSF mRNA levels were determined by RT-qPCR, normalized to GAPDH mRNA levels, and expressed relative to the value at time 0,
set as 100 %. The results are the mean ± SD for three independent experiments. *p < 0.05, compared to cells not treated with SB203580 at the
corresponding time point. b RAW264.7 cells were pretreated for 30 min with DMSO or 10 μM SB203580, then actinomycin D (4 μg/ml) was added
for 0, 0.5, 1, 2 or 3 h. Then the G-CSF mRNA levels were determined by RT-qPCR and normalized to GAPDH mRNA levels and expressed relative
to the value at time 0 (relative value =100 %). The results are the mean for two independent experiments
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(Fig. 6b) in Gp-LUC-transfected cells, but resulted in a 1-
fold increase in both the luciferase mRNA levels (Fig. 6a)
and activity (Fig. 6b) in Gp-LUC-3’UTR-transfected cells.
These results suggest that the 3’UTR of G-CSF mRNA
may be involved in SB203580-induced mRNA stabilization,
and show that the changes in luciferase activity paralleled
those in the luciferase mRNA levels. Gp-LUC-3’UTR was
also transfected into p38α MAPK knockdown cells or
control knockdown cells, which were then treated as above
with DMSO or SB203580 for 20 h and, as shown in Fig. 6c,
SB203580 treatment resulted in a 1.3-fold increase in lucif-
erase activity in both the p38α MAPK knockdown or
control knockdown cells. This result supports our finding
that SB203580 increases the G-CSF mRNA levels by an
increase in its stability, probably mediated by the 3’UTR of
G-CSF mRNA and independently of p38αMAPK activity.
We then tested whether SB203580 pretreatment also
induced an increase in luciferase activity in LPS-treated
Gp-LUC- or Gp-LUC-3’UTR-transfected cells by treat-
ing the cells either with DMSO or SB203580 for 20 h or
with these reagents for 30 min before and during incu-
bation with LPS for 20 h. As shown in the top two
panels of Fig. 7b, in the presence of LPS (two right
columns in each panel), SB203580 increased luciferase
activity by 110 % in cells transfected with Gp-LUC-
3’UTR (right panel), but did not increase luciferase
activity in cells transfected with Gp-LUC (left panel). To
evaluate the role of the SLDE in the 3’UTR in the
SB203580-induced increase in luciferase activity, we
generated three Gp-LUC-3’UTR SLDE mutants, SLDE
M1, M2, and M3 (Fig. 7a). Mutant M1 was constructed
so as to disrupt the stem by mutating UUAA nucleotides
on one side of the stem to CGAC, whereas the stem
structure was retained in mutants M2 and M3, but a U-
A base pair in the stem was replaced by a G-C base pair
in M2 and two consecutive U-A and A-U base pairs
were exchanged in M3. These reporter plasmids were
transfected into RAW264.7 cells and the transfected
cells were then incubated as above. The bottom 3 panels
in Fig. 7b show that all 3 SLDE mutants lost the ability
to response to SB203580 treatment in the absence or
presence of LPS, while SLDE mutants two and three in
which the stem structure was retained, but not mutant
one in which it was destroyed, were still able to respond
to LPS treatment. These results further support the idea
that the SLDE in the 3’UTR of G-CSF mRNA is critical
for the increase in the G-CSF mRNA levels induced by
SB203580.
Discussion
This study shows that SB203580 induced an increase in
both basal and LPS-induced the G-CSF mRNA levels
and that this effect was also seen in p38α MAPK knock-
down RAW264.7 macrophages. Our results show that
SB203580 stabilizes G-CSF mRNA and that this process
requires the SLDE in the 3’UTR, but is independent of
the inhibitory effect of SB203580 on p38α MAPK activ-
ity. Despite the fact that SB203580 is widely used as a
p38 MAPK inhibitor, several biochemical studies have
shown that it is also involved in many p38 MPAK-
Fig. 6 SB203580 induces the luciferase mRNA and activity in RAW264.7 cells transfected with Gp-LUC-3’UTR. (a and b) RAW264.7 cells
were co-transfected with reporter plasmid (Gp-LUC or Gp-LUC-3’UTR) and control plasmid (phRLTK), then, 4 h later, were treated with
DMSO or 10 μM SB203580 for 20 h. (a) Photinus luciferase mRNA levels were determined by RT-qPCR, normalized to Renilla luciferase
mRNA levels, and expressed relative to the value in Gp-LUC-transfected cells treated with DMSO, set as 1. (b) Photinus and Renilla luciferase activities
were measured and Photinus luciferase activity normalized to Renilla luciferase activity and expressed relative to the value in the Gp-LUC-transfected
cells treated with DMSO, set as 1. (c) p38α MAPK knockdown cells and control knockdown cells (Luc shRNA) were co-transfected with Gp-LUC-3’UTR
and phRLTK and treated as described above, then luciferase activities were determined as in (b) and expressed relative to the value in
the DMSO-treated Luc controls, set as 1. The values are the mean ± SD for three independent experiments. *p < 0.05 as indicated. n.s., not significant
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independent cellular activities [13–15]. This could be
due to the facts that SB203580 inhibits several other
protein kinases [15, 16] and induces activation of several
others [17, 18]. Some SB203580-mediated cellular
effects, such as inhibition of the 2,3,7,8-tetrachlorodi-
benzo-p-dioxin-induced increase in CYP1A1 mRNA
levels and of α-melanocyte stimulating hormone-
induced melanogenesis and spontaneous melanin
synthesis, can be seen in cells treated with other pyridi-
nyl imidazole inhibitors and also with SB202474, an
SB203580 analog that does not inhibit p38 MAPK
activity [13, 14]. These results suggested that all pyridi-
nyl imidazoles might have these p38 MAPK inhibition-
independent effects. However, in the present study, we
found that SB203580, SB202190, and PD169316 were all
effective in increasing the G-CSF mRNA levels, while
SB239063 and SB202474 had no such effect, showing
that only certain pyridinyl imidazole compounds can in-
duce an increase in the G-CSF mRNA levels. Analysis of
the chemical structures of these compounds suggested
that the phenyl ring at the C-2 position and the 4-
fluorophenyl group at the C-4 position of the imidazole
ring are indispensable. However, the precise structure of
compounds that can increase the G-CSF mRNA levels
remains to be established.
The present study showed that SB203580 significantly
increased the stability of G-CSF mRNA. Analyses using
the luciferase-G-CSF 3’UTR chimeric reporter gene
Fig. 7 Mutation of the SLDE abolishes the SB203580-induced increase in luciferase activity in cells transfected with Gp-LUC-3’UTR. a The sequence and
structure of the wild-type SLDE (WT) in the 3’UTR of G-CSF and the three SLDE mutants (M1, M2, and M3). b RAW264.7 cells were co-transfected with
one of the reporter plasmids (Gp-LUC, Gp-LUC-3’UTR, or Gp-LUC-3’UTR mutants one to three) and control plasmid (phRLTK), then, 4 h later, were either
treated with DMSO (D) or 10 μM SB203580 (SB) for 20 h (left 2 columns) or were pretreated for 30 min with DMSO or 10 μM SB203580, then LPS was
added and the cells incubated for a further 20 h (right 2 columns), then the Photinus and Renilla luciferase activities were measured. The Photinus
luciferase activity was normalized to the Renilla luciferase activity and expressed relative to the value for the DMSO-treated control for the same
reporter, set as 1. The values are the mean ± SD for three independent experiments. *p < 0.05, compared to the corresponding DMSO-treated control.
n.s., not significant
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demonstrated that insertion of the 3’UTR downstream
of luciferase resulted in downregulation of the luciferase
mRNA and an increase in the luciferase mRNA levels in
response to SB203580 treatment. Since luciferase
transcription in both the Gp-LUC and Gp-LUC-3’UTR
reporter constructs was driven by the GAPDH promoter,
the decrease in the luciferase mRNA levels in cells trans-
fected with Gp-LUC-3’UTR was probably due to
destabilization of the luciferase mRNA caused by the
3’UTR from G-CSF mRNA. Although the AURE is the
most common destabilizing element in mRNA, Brown
et al. [6] demonstrated that the AUREs in G-CSF mRNA
do not act as destabilizing elements in 5637 bladder
carcinoma cells and identified the SLDE as a destabiliz-
ing element that functions independently of the AUREs.
In this study, we mutated the sequence of the SLDE
while leaving the AUREs intact and found that the ability
of SB203580 to increase luciferase activity was abolished
and, since the change of luciferase activity in paralleled
the change in the luciferase mRNA levels, this suggests
that the SLDE, but not AUREs, are responsible for the
SB203580-induced increase in the stability of G-CSF
mRNA. The precise mechanism is not known for that
AUREs is not functional in G-CSF mRNA, the function
of AUREs might be masked by the SLDE or by other un-
known mechanism(s). The SLDE has been reported to in-
crease the rate of mRNA deadenylation, and the sequence
within the stem was found not to be critical for the desta-
bilizing effect as long as the stem structure was maintained
[4]. However, our results suggest that both the structure
and the sequence of the stem are critical for G-CSF mRNA
induction by SB203580. Taken together, our results suggest
that the SLDE functions as a destabilizing element in un-
treated macrophages and becomes a stabilizing element in
SB203580- and/or LPS-treated macrophages.
Cancer patients usually develop neutropenia after
chemotherapy or radiation therapy [19] and such
patients are at risk of bacterial infections, so an effective
and low cost therapy that can accelerate the recovery of
neutrophil numbers is important. This effect can be
achieved in neutropenia patients by injection of recom-
binant G-CSF [20]; however, this requires subcutaneous
or intravenous injection and is expensive. Because of
this, efforts have been made to identify small molecular
weight compounds that can be delivered at low cost as
an effective therapy. A small synthetic compound, SCH
14988 (a pyridinyl-naphthyridinyl-sulfonyl acetamide),
has been shown to specifically stimulate G-CSF production
in vitro and in vivo [21]. In addition, Aoki et al. [22] identi-
fied a stimulatory monoclonal antibody (mAb 3-4H7) from
autoimmune mice that selectively stimulates G-CSF gene
expression in mouse macrophages. The mechanism(s) by
which SCH 14988 and mAb 3-4H7 stimulate G-CSF pro-
duction is unclear, but post-transcriptional regulation has
been suggested in the case of SCH 14988-stimulated G-
CSF production [21]. Our study demonstrated that a small
molecular weight compound, SB203580, can increase the
G-CSF mRNA levels through a post-transcriptional mech-
anism by increasing the stability of mRNA. Our results
show that the development of small molecular compounds
that increase the stability of G-CSF mRNA by acting on a
stabilizing element in the 3’UTR could be a novel approach
to stimulate G-CSF production.
p38 MAPK is a major phosphoprotein activated by LPS
and several inflammatory cytokines [7, 23]. After phos-
phorylation/activation, p38 MAPK activates downstream
mediators that upregulate the production of multiple pro-
inflammatory cytokines, including TNFα, IL-1β, IL-6, and
IL-8, and the induction of key inflammatory enzymes, in-
cluding COX-2 and inducible nitric oxide synthase [7, 23].
p38 MAPK has therefore been suggested as a therapeutic
target for treatment of inflammatory diseases [23].
However, when various p38 MAPK inhibitors were used
in two similar acute lung inflammation rodent models,
conflicting results were obtained. Arcaroli et al. [24]
demonstrated that systemic inhibition of p38 MAPK by
SB203580 resulted in increased pulmonary neutrophil ac-
cumulation in LPS-induced acute lung inflammation,
whereas other workers found that SB239063, another p38
MAPK inhibitor, significantly reduced pulmonary neutro-
phil infiltration [25, 26]. Since G-CSF is a key regulator of
the production of neutrophils, these conflicting results
might be due to SB203580 inducing G-CSF production,
leading to neutrophil accumulation, whereas SB239063
might have no effect on G-CSF production. G-CSF
levels were not measured in these studies, so it would
be interesting to investigate the effects of SB203580 and
SB239063 on G-CSF production and pulmonary neutro-
phil infiltration in LPS-induced acute lung injury.
Conclusions
We have shown that SB203580, a p38 MAPK inhibitor, in-
creases the G-CSF mRNA levels by increasing the stability
of mRNA and that this effect is independent of its inhibi-
tory effect on p38 MAPK activity. Our results also suggest
that the SLDE in the 3’UTR of G-CSF mRNA functions as
a destabilizing element in the absence of treatment and
becomes a stabilizing element in response to SB203580
treatment. The results of this study provide a poten-
tial approach for boosting endogenous production of
G-CSF during neutropenia. Different effects of different
pyridynyl imidazole compounds on G-CSF production
might explain the conflicting results obtained using these
compounds in different anti-inflammation studies. Exactly
how the SLDE is involved in increasing the stability of G-
CSF mRNA is not known at this time, and further studies
are needed to clarify the mechanism.
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